생물학적 제제 : 기술 및 세계 시장

Highlights:

The global market for biological therapeutic drugs is expected to increase from $452.9 billion in 2023 to $823.4 billion by the end of 2028, with a compound annual growth rate (CAGR) of 12.7% during the forecast period of 2023-2028.

Therapeutics and proteins market for biological therapeutic drugs is expected to increase from $248.5 billion in 2023 to $470.4 billion by the end of 2028, with a CAGR of 13.6% during the forecast period of 2023-2028.

Cell and gene therapy market for biological therapeutic drugs is expected to increase from $60.4 billion in 2023 to $119.4 billion by the end of 2028, with a CAGR of 14.6% during the forecast period of 2023-2028.

Report Scope:

The current report offers a detailed picture of the biologics market.

This report highlights the current and future market potential for biologics and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2028, as well as key market players.

This report details market shares for biologics based on product, source, application and geography. Based on product, the market is segmented into therapeutic proteins, cell and gene therapy, vaccines, and other segments. Based on application, the market is segmented into cancer, autoimmune conditions, aesthetics, eye disorders, and others. Based on source, the market is segmented into human, animal, micro-organism, fermented cell and others

Based on geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are covered in regional segments. For market estimates, data has been provided for 2022 as the base year, with forecasts for 2023 through 2028. Estimated values are based on product manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:

• 38 data tables and 59 additional tables
• An overview of the global markets for biologic therapeutic drugs.
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.
• Estimate of the actual market size and revenue forecast, and a corresponding market share analysis by product type, therapeutic area and region.
• A discussion of the market's opportunities and challenges, as well as emerging technologies and regulations.
• Overview of the sustainability trends, with emphasis on consumer attitudes, companies' ESG scores, the future of ESG, case studies and the ESG practices of companies.
• A discussion of the technological means that the leading biopharmaceutical companies are using.
• Evaluation of the ongoing clinical trials and R&D activity for biologics production.
• A look at the key drugs on the market and recent approvals, sales statistics and past performance of the top selling biologics, as well as their patent expiries.
• Review of emerging technologies and patents.
• An overview of the competitive landscape, including a look at the major vendors' market shares, recent M&A activity, and venture funding outlook.
• Company profiles of major players within the industry, including Amgen Inc., Abbive Inc., Eli Lilly And Co., Novartis Ag, and Glaxosmithkline Plc

Table of Contents

Chapter 1 Introduction

• Introduction
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in this Update?
• Methodology
• Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Overview

Chapter 3 Market and Technology Background

• Biopharmaceutical Industry Structure
• Origins of Biotechnology
• Involvement of Large Pharmaceutical Companies
• Overview of Biologics
• Biologics Manufacturing
• Biopharmaceutical Manufacturing Process
• The Preparation Process
• Expression Systems for Therapeutic Protein Production
• Advantages of E. coli for Microbial Production
• Mammalian Cell Therapeutic Protein Production
• FDA Regulation of Biologics

Chapter 4 Market Dynamics

• Market Drivers
• Overview
• Rising Prevalence of Chronic Diseases
• Advancement in Biologics
• Development in Cell and Gene Therapy Methodology
• Increase in Infectious and Chronic Diseases
• Market Restraints
• Emergence of Biosimilars
• Expensive Cost of Biologics
• Market Opportunities
• Opportunities in Emerging Nations

Chapter 5 Market Breakdown by Product Segment

• Global Market for Biological Therapeutic Drugs by Product
• Therapeutic Proteins
• Vaccines
• Cell and Gene Therapy
• Others

Chapter 6 Market Breakdown by Application

• Global Market for Biological Therapeutic Drugs by Application
• Cancer
• Autoimmune Conditions
• Aesthetics
• Eye Disorder
• Others

Chapter 7 Market Breakdown by Source

• Global Market for Biological Therapeutic Drugs by Source
• Human
• Animal
• Microorganisms
• Fermented Cells
• Other Sources

Chapter 8 Market Breakdown by Region

• Global Market for Biological Therapeutic Drugs by Region
• North America
• Europe
• Asia-Pacific
• Rest of World
• GCC Countries
• Brazil
• Rest of World Countries

Chapter 9 Emerging Technology for Biologics Manufacturing

• Introduction
• AcceTT & BacSec Technologies
• Single-use Technologies
• Cell and Gene Therapy (CGT)
• Doggybone DNA (dbDNA)
• Animal Plasma Isolation
• Hybridoma Generation
• B Cell Screening
• Display Technologies
• Emerging Biologics Discovery and Generation Technologies
• Emerging Trends in Biologic Production Technologies
• Example of New Developments by Companies
• Samsung Biologics
• AstraZeneca
• Genentech Inc. (Member of Roche family)

Chapter 10 Sustainability in the Biopharmaceuticals and Biologics Industry: An ESG Perspective

• Importance of ESG in the Biopharmaceuticals Manufacturing Industry
• ESG Ratings and Metrics: Understanding the Data
• ESG Practices in the Biopharmaceuticals and Biologics Manufacturing Industry
• BCC Research Viewpoint

Chapter 11 M&A and Venture Funding Outlook

• M&A Analysis
• M&A Deals 2018-2023
• Top Biologic Drug Startups
• Flourishing Biotech Startups (2023)

Chapter 12 FDA Approved Monoclonal Antibodies, 1986-2023

Chapter 13 Competitive Landscape

• Porter's Five Forces Analysis
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of New Entrants
• Threat of Substitutes
• Competitive Rivalry/Degree of Competition

Chapter 14 Company Profiles

• ABBVIE INC.
• AMGEN INC.
• BAXTER INTERNATIONAL INC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• CSL LTD.
• DENDREON PHARMACEUTICALS LLC.
• ELI LILLY AND CO.
• F. HOFFMANN-LA ROCHE LTD.
• GLAXOSMITHKLINE PLC
• GLYCOTOPE GMBH
• GRIFOLS S.A.
• JSC PHARMSTANDARD
• KEDRION S.P.A.
• LONZA
• MERCK & CO. INC.
• NOVARTIS AG
• OCTAPHARMA AG
• RELIANCE LIFE SCIENCES
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.